{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T06:42:03Z","timestamp":1774161723947,"version":"3.50.1"},"reference-count":46,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T00:00:00Z","timestamp":1496966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570203"],"award-info":[{"award-number":["81570203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570204"],"award-info":[{"award-number":["81570204"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81500174"],"award-info":[{"award-number":["81500174"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2017,9]]},"abstract":"Summary<\/jats:title>\n \n We compared the efficacy and safety of gemcitabine, cisplatin, prednisone and thalidomide (\n GDPT<\/jats:styled-content>\n ) with standard\n CHOP<\/jats:styled-content>\n regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) for patients with newly diagnosed peripheral T\u2010cell lymphoma (\n PTCL<\/jats:styled-content>\n ) in a prospective randomized controlled and open\u2010label clinical trial. Between July 2010 and June 2016, 103 patients were randomly allocated into two groups, of whom 52 were treated with\n GDPT<\/jats:styled-content>\n therapy and 51 with\n CHOP<\/jats:styled-content>\n therapy. The 2\u2010year progression\u2010free survival (\n PFS<\/jats:styled-content>\n ) and overall survival (\n OS<\/jats:styled-content>\n ) rates were better in the\n GDPT<\/jats:styled-content>\n group than in the\n CHOP<\/jats:styled-content>\n group (57% vs. 35% for 2\u2010year\n PFS<\/jats:styled-content>\n ,\n P\u00a0<\/jats:italic>\n =\n \u00a0<\/jats:italic>\n 0\u00b70035; 71%\n vs<\/jats:italic>\n 50% for 2\u2010year\n OS<\/jats:styled-content>\n ,\n P\u00a0<\/jats:italic>\n =\n \u00a0<\/jats:italic>\n 0\u00b70001). The complete remission rate (\n CRR<\/jats:styled-content>\n ) and the overall response rate (\n ORR<\/jats:styled-content>\n ) in the\n GDPT<\/jats:styled-content>\n group were higher than in the\n CHOP<\/jats:styled-content>\n group (52% vs. 33%,\n P\u00a0<\/jats:italic>\n =\n \u00a0<\/jats:italic>\n 0\u00b7044 for\n CRR<\/jats:styled-content>\n ; 67% vs. 49%,\n P\u00a0<\/jats:italic>\n =\n \u00a0<\/jats:italic>\n 0\u00b7046 for\n ORR<\/jats:styled-content>\n ). Haemocytopenia was the predominant adverse effect, and acute toxicity was moderate, tolerable and well managed in both arms.\n mRNA<\/jats:styled-content>\n expression of\n \n ERCC<\/jats:styled-content>\n 1\n <\/jats:italic>\n ,\n \n RRM<\/jats:styled-content>\n 1\n <\/jats:italic>\n ,\n \n TUBB<\/jats:styled-content>\n 3\n <\/jats:italic>\n and\n \n TOP<\/jats:styled-content>\n 2A\n <\/jats:italic>\n genes varied among patients but the difference did not reach statistical significance, mainly due to the relatively small sample size. The precise characters of these biomarkers remain to be identified. In conclusion,\n GDPT<\/jats:styled-content>\n is a promising new regimen as potential first\u2010line therapy against\n PTCL<\/jats:styled-content>\n . This study was registered at\n www.clinicaltrials.gov<\/jats:ext-link>\n as #\n NCT<\/jats:styled-content>\n 01664975.\n <\/jats:p>","DOI":"10.1111\/bjh.14763","type":"journal-article","created":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T04:08:47Z","timestamp":1496981327000},"page":"772-780","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus\n CHOP<\/scp>\n in patients with newly diagnosed peripheral T\u2010cell lymphoma with analysis of biomarkers"],"prefix":"10.1111","volume":"178","author":[{"given":"Ling","family":"Li","sequence":"first","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Centre of Henan Province Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5598-1019","authenticated-orcid":false,"given":"Wenjing","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Centre of Henan Province Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Centre of Henan Province Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Centre of Henan Province Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaorui","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Centre of Henan Province Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Centre of Henan Province Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Centre of Henan Province Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenchang","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Centre of Henan Province Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Centre of Henan Province Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Centre of Henan Province Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Nan","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Centre of Henan Province Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqin","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Centre of Henan Province Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2876-5182","authenticated-orcid":false,"given":"Zhaoming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Centre of Henan Province Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Centre of Henan Province Zhengzhou Henan China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,6,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/623924"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10737"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00116-7"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.7869"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.1101"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-578575"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.08.001"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0351-4"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1995"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00023-X"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.009"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12488"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.2174\/156800907783220453"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-231548"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2016.00069"},{"key":"e_1_2_8_18_1","first-page":"76","article-title":"Prognostic significance of T\u2010cell phenotype in aggressive non\u2010Hodgkin's lymphomas","volume":"92","author":"Gisselbrecht C.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_8_19_1","first-page":"431","article-title":"Glucocorticoid receptors and steroid sensitivity in normal and neoplastia human lymphoid tissues: a review","volume":"44","author":"Homo\u2010Delarche F.","year":"1984","journal-title":"Cancer Research"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.11.4"},{"key":"e_1_2_8_21_1","first-page":"529","article-title":"Clinical analysis of thalidomide in 36 untreated patients with T\u2010cell lymphoma","volume":"37","author":"Huang H.Y.","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"e_1_2_8_22_1","volume-title":"World Health Organization Classification of Tumours: Patholgy and Genetics of Tumours of Haematopietic and Lymphoid Tissues","author":"Jaffe E.S.","year":"2001"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M100938200"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008339425708"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2014_029"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-013-0232-x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27733"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21449"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e31826aeeb2"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh471"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1588"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3151"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2468-y"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290016926"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.17.3766"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh392"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2010.07.007"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620713481980"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.0188"},{"key":"e_1_2_8_43_1","first-page":"207","article-title":"ERCC1 and RRM1 as a predictive parameter for non\u2010small cell lung, ovarian or pancreas cancer treated with cisplatin and\/or gemcitabine","volume":"19","author":"Ulker M.","year":"2015","journal-title":"Contemporary Oncology"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2014.307"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.739286"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008409601731"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.14763","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.14763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:08:02Z","timestamp":1696338482000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.14763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,9]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1111\/bjh.14763"],"URL":"https:\/\/doi.org\/10.1111\/bjh.14763","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727697987.793539753","asserted-by":"object"}]},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,9]]},"assertion":[{"value":"2016-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}